Published in J Urol on December 01, 2000
Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72
BCG immunotherapy for bladder cancer--the effects of substrain differences. Nat Rev Urol (2013) 1.60
Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol (2012) 1.27
Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol (2008) 1.25
Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy (2009) 1.19
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ (2013) 1.13
Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol (2004) 1.04
Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol (2006) 1.03
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One (2014) 1.00
Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol (2010) 0.92
Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol (2007) 0.92
Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now? Adv Urol (2012) 0.91
Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol (2010) 0.87
Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun (2006) 0.87
Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. Clin Exp Immunol (2007) 0.86
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget (2013) 0.84
Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers (Basel) (2011) 0.83
Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Clin Cancer Res (2014) 0.82
Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol (2002) 0.80
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immun (2009) 0.77
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studies. BBA Clin (2015) 0.77
Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med (2012) 0.77
Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. Oncoimmunology (2016) 0.75
High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology (2017) 0.75
Biomarkers for precision medicine in bladder cancer. Int J Clin Oncol (2016) 0.75
Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. PLoS One (2017) 0.75
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest (2017) 0.75
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (1994) 5.97
Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone (1996) 2.11
Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology (1990) 2.02
Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res (1990) 1.97
Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol (2001) 1.86
Endopyelotomy for primary ureteropelvic junction obstruction: risk factors determine the success rate. J Urol (1998) 1.67
Osteopontin: possible role in prostate cancer progression. Clin Cancer Res (1999) 1.57
Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol (2002) 1.52
Metabolic consequences of continent urinary diversion. J Urol (1999) 1.46
Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur J Endocrinol (1996) 1.46
Female orthotopic bladder substitution: a good operation in the right circumstances. J Urol (2000) 1.22
Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol (1996) 1.14
Colony-stimulating factor-1 injections improve but do not cure skeletal sclerosis in osteopetrotic (op) mice. Bone (1995) 1.12
Metastatic disease of the ureter: patterns of tumoral spread and radiologic findings. Abdom Imaging (1993) 1.09
How to avoid clean intermittent catheterization in men with ileal bladder substitution. J Urol (2008) 1.07
A role for N-cadherin in the development of the differentiated osteoblastic phenotype. J Bone Miner Res (2000) 1.00
Role of colony-stimulating factor-1 in bone metabolism. J Cell Biochem (1994) 0.99
Carcinosarcoma of the urinary bladder: a distinct variant characterized by small cell undifferentiated carcinoma with neuroendocrine features. Virchows Arch A Pathol Anat Histopathol (1992) 0.98
Decreased sensitivity in the membranous urethra after orthotopic ileal bladder substitute. J Urol (1999) 0.98
Effect of macrophage colony-stimulating factor on in vitro osteoclast generation and bone resorption. Endocrinology (1992) 0.91
Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol (2001) 0.91
Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol (1997) 0.90
Transforming growth factor-beta reduces the phenotypic expression of osteoblastic MC3T3-E1 cells in monolayer culture. Bone (1987) 0.90
Primary or secondary extragonadal germ cell tumors? J Urol (1986) 0.90
Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology (2008) 0.89
Cystadenoma of the seminal vesicle: case report and literature review. J Urol (1992) 0.88
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol (1999) 0.88
Extracorporeal shock wave lithotripsy in situ or after push-up for upper ureteral calculi: a prospective randomized trial. J Urol (1993) 0.87
How to fill silicone catheter balloon. Urology (1983) 0.86
Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. Swiss Med Wkly (2009) 0.86
Small-cell undifferentiated carcinoma of the renal pelvis 26 years after subdiaphragmatic irradiation for non-Hodgkin's lymphoma. Br J Urol (1995) 0.86
Orthotopic bladder substitution. Curr Opin Urol (2000) 0.85
Antegrade endopyelotomy for treatment of ureteropelvic junction obstruction in transplanted kidneys. J Endourol (2006) 0.85
The effect of nerve sparing cystectomy technique on postoperative continence after orthotopic bladder substitution. J Urol (1997) 0.85
Prognosis after extracorporeal shock wave lithotripsy of radiopaque renal calculi: a multivariate analysis. Eur Urol (1994) 0.85
Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol (2008) 0.85
Bilateral testicular germ cell tumors: a report of 20 cases. J Urol (1987) 0.84
Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. Br J Urol (1995) 0.84
Synthesis of membrane- and matrix-bound colony-stimulating factor-1 by cultured osteoblasts. J Cell Physiol (1996) 0.83
Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland. J Urol (1984) 0.82
Managing patients after an ileal orthotopic bladder substitution. BJU Int (2004) 0.82
Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab (1993) 0.82
Cystectomy and urinary diversion. Semin Surg Oncol (1997) 0.81
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate (2001) 0.81
Detection of transcripts and binding sites for colony-stimulating factor-1 during bone development. Bone (1995) 0.81
Noninvasive anesthesia, analgesia and radiation-free extracorporeal shock wave lithotripsy for stones in the most distal ureter: experience with 165 patients. J Urol (2002) 0.81
Invasion depth is the most important prognostic factor for transitional-cell carcinoma in a prospective trial of radical cystectomy and adjuvant chemotherapy. Int J Cancer (1994) 0.81
Ultrasonography of testicular tumors. Urol Int (1990) 0.80
Reconstruction of the urinary tract after radical cystectomy: the case for continent urinary diversion. Urology (1997) 0.80
The ileal orthotopic bladder. Urology (1995) 0.79
Which patients are suitable for continent diversion or bladder substitution following cystectomy or other definitive local treatment? Int J Urol (1995) 0.78
No evidence of osteopenia 5 to 8 years after ileal orthotopic bladder substitution. J Urol (1996) 0.77
A model for a bladder replacement plasty by an ileal reservoir--an experimental study in dogs. Urol Res (1985) 0.77
Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer. World J Urol (1994) 0.77
Downregulation of colony-stimulating factor-1 (CSF-1) binding by CSF-1 in isolated osteoclasts. Calcif Tissue Int (1995) 0.77
Quantitative measurements of humoral immune response in mice to a FANFT induced bladder tumor. Urol Res (1985) 0.77
Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur Urol (2005) 0.77
Pathogenesis and treatment of hypertension in renal tuberculosis. Eur Urol (1984) 0.77
Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo. Br J Pharmacol (2002) 0.77
Are autopsies of help to the parents of SIDS victims? A follow-up on SIDS families. Int J Legal Med (2006) 0.77
[Adjuvant chemotherapy after cystectomy for bladder tumors staged as superior or equal to pT3]. Prog Urol (1997) 0.76
Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate (1997) 0.76
Outcome of patients with untreated cancer of the prostate. Eur Urol (1993) 0.76
Urethral sensitivity and the impact on urinary continence in patients with an ileal bladder substitute after cystectomy. J Urol (2001) 0.76
[Internal fixation of meta- and diaphyseal intercalary bone defects after tumour resection with intramedullary nailing and porous polymethylmetacrylate (PMMA) spacer]. Orthopade (2007) 0.76
[The role of pelvic lymphadenectomy in clinically localised prostate cancer]. Urologe A (2005) 0.75
[Tips and tricks for nerve-sparing cystectomy]. Urologe A (2004) 0.75
Influence of stent size on the success of antegrade endopyelotomy for primary ureteropelvic junction obstruction: results of 2 consecutive series. J Urol (2001) 0.75
Continent urinary reservoirs. J Urol (1994) 0.75
[Rare seminoma metastasis to the corpus spongiosum and urethra]. Urologe A (2003) 0.75
Minimizing morbidity from reconstructive bladder surgery. J Urol (1997) 0.75
Preliminary results of a Phase I/II study with pi-meson (pion) treatment for bladder cancer. Cancer (1985) 0.75
[Prognostic and therapeutic aspects of prostatic carcinoma]. Schweiz Rundsch Med Prax (1988) 0.75
[Substitute bladder following radical cystectomy]. Schweiz Rundsch Med Prax (1988) 0.75
[Clinical and therapeutic aspects of prostatic cancer]. Schweiz Rundsch Med Prax (1983) 0.75
[Surgical therapy of vascular impotence]. Schweiz Med Wochenschr (1988) 0.75
[Therapy of erectile dysfunction using papaverine--2 1/2 years' experience]. Schweiz Med Wochenschr (1988) 0.75
[A procedure for bladder replacement using a low-pressure ileal reservoir]. Ann Urol (Paris) (1993) 0.75
[Intracavernous self-injection in impotence]. Ther Umsch (1992) 0.75
[Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin]. J Urol (Paris) (1986) 0.75
Urethral replacement using ileum with an intussuscepted ileal valve for continence. J Urol (1985) 0.75
[Treatment of impotence with intracavernous papaverin injections]. Helv Chir Acta (1989) 0.75
Preoperative preparation of the bowel for urological surgery: a review. Eur Urol (1986) 0.75
[Factors determining the survival rate after radical cystectomy]. Helv Chir Acta (1982) 0.75
[Treatment of carcinoma in situ of the urinary bladder with BCG]. Helv Chir Acta (1989) 0.75
[Diagnostic and prognostic value of serum phosphatases and PSA (prostate-specific antigen) in prostatic carcinoma]. Schweiz Rundsch Med Prax (1988) 0.75
[Results after radical prostatectomy for prostate carcinoma]. Schweiz Med Wochenschr (1986) 0.75
Treatment of superficial bladder tumors with intravesical recombinant interferon alpha-2a. Urol Int (1988) 0.75
[Diagnosis and therapy of erectile impotence with special reference to papaverine]. Schweiz Med Wochenschr (1986) 0.75
[A case of pseudopriapism: pericavernous hematoma of the penis]. J Urol (Paris) (1984) 0.75
Bladder substitutes made of crossfolded ileum. Scand J Urol Nephrol Suppl (1992) 0.75
Efficacy and safety of human mesenchymal stromal cells in healing of critical-size bone defects in immunodeficient rats. Physiol Res (2016) 0.75
Preliminary results on the use of the humoral immune response as a serum marker in patients with bladder tumors. Urol Res (1985) 0.75
Antibodies to cultured tumor cells detected in sera of renal cell carcinoma patients by a quantitative avidin-biotin method. J Urol (1986) 0.75
[Recurrent cystitis in women]. Schweiz Rundsch Med Prax (1982) 0.75